In a 32‑year‑old man with unilateral central retinal vein occlusion (CRVO) and macular edema, prolonged activated partial thromboplastin time (APTT), elevated serum immunoglobulin A (IgA), normal lupus anticoagulant and anticardiolipin antibodies, and on olanzapine (generic: olanzapine) for five years, what are the possible underlying etiologies and how should a case report be presented?

Case Report: CRVO in Young Patient on Olanzapine with Elevated IgA and Prolonged APTT

Clinical Presentation

A 32-year-old male presents with unilateral CRVO and macular edema, prolonged APTT, elevated serum IgA, normal lupus anticoagulant and anticardiolipin antibodies, on olanzapine for 5 years, with engorged vessels but no macular edema in the contralateral eye—this represents a hypercoagulable state likely driven by olanzapine-induced prothrombotic effects, with IgA-mediated coagulopathy as a contributing factor.

Underlying Etiologies

Primary Suspect: Olanzapine-Induced Hypercoagulability

Olanzapine is the most likely culprit in this case. 1 The drug blocks 5-HT2A serotonin receptors, which increases platelet aggregation and blood coagulability. This mechanism has been documented in a 50-year-old patient who developed nonischemic CRVO after 3 years of olanzapine use with no other risk factors 1. Your patient's 5-year exposure significantly increases this risk.

The FDA label confirms olanzapine's association with venous thromboembolic events, including pulmonary embolism and deep venous thrombosis 2. While retinal vein occlusion is not explicitly listed, the prothrombotic mechanism is well-established.

Secondary Factor: IgA-Mediated Coagulopathy

The elevated IgA with prolonged APTT suggests an acquired coagulation inhibitor or IgA-associated vasculopathy. While you've ruled out antiphospholipid syndrome (negative lupus anticoagulant and anticardiolipin antibodies), elevated IgA can:

• Cause hyperviscosity
• Form immune complexes affecting vascular endothelium
• Indicate underlying IgA nephropathy with associated hypercoagulability

Age-Specific Considerations

CRVO in patients under 40 years is uncommon and demands thorough hypercoagulable workup 3. Your patient at 32 years falls into this high-risk category requiring expanded investigation 4.

Diagnostic Workup

Already Completed (Negative)

• Lupus anticoagulant: Normal
• Anticardiolipin A and B: Normal

Still Required

Complete the hypercoagulable panel immediately:

• Homocysteine level (elevated in 27% of young CRVO patients) 4
• Activated protein C resistance (Factor V Leiden)
• Protein C and S activity
• Antithrombin III activity
• Anti-β2-glycoprotein 1 antibodies (can be positive when anticardiolipin is negative) 5, 6
• Prothrombin gene mutation
• Complete blood count with differential
• Comprehensive metabolic panel
• Lipid profile
• Hemoglobin A1c

Investigate the elevated IgA:

• Serum protein electrophoresis
• Urine protein/creatinine ratio (rule out IgA nephropathy)
• Complement levels (C3, C4)

Ophthalmologic assessment:

• Fluorescein angiography to determine ischemic vs. nonischemic CRVO 3
• Optical coherence tomography for macular edema quantification
• Monitor for neovascularization (iris and retina) 3
• Assess the fellow eye carefully—engorged vessels suggest impending involvement

Management Algorithm

Immediate Actions

1. Consult psychiatry regarding olanzapine discontinuation or substitution. The drug's prothrombotic risk outweighs psychiatric benefits when causing sight-threatening complications 1. Consider switching to an antipsychotic with lower thrombotic risk.

2. Initiate anticoagulation consultation. Given prolonged APTT and probable hypercoagulable state, systemic anticoagulation may be warranted 7, 6.

3. Treat macular edema aggressively:

   • First-line: Anti-VEGF intravitreal injections (ranibizumab or aflibercept, FDA-approved) 3
   • Alternative: Intravitreal steroids if anti-VEGF contraindicated 3
   • Monitor monthly initially

Monitoring Protocol

• Weekly ophthalmologic exams for first month to detect:

  • Conversion to ischemic CRVO (requires panretinal photocoagulation) 3
  • Neovascularization (iris or retina)
  • Fellow eye involvement

• Monthly follow-up thereafter with OCT and clinical exam 3

• Repeat antiphospholipid antibodies in 12 weeks if initial workup incomplete (single negative test insufficient to exclude APS) 5, 8

Critical Pitfalls to Avoid

1. Do not assume negative anticardiolipin antibodies exclude antiphospholipid syndrome. Anti-β2-glycoprotein 1 antibodies must be checked, and testing should be repeated at 12 weeks 6, 9.

2. Do not overlook the fellow eye. Engorged vessels without edema may represent impending CRVO—this patient needs bilateral monitoring 5.

3. Do not continue olanzapine without psychiatric consultation. The temporal relationship (5 years of exposure) and mechanism (5-HT2A blockade) strongly implicate this medication 1.

4. Do not delay anticoagulation workup. Young patients with CRVO have 27% incidence of hypercoagulable states, and bilateral involvement risk is higher 4.

5. Monitor for conversion to ischemic CRVO. Nonischemic can become ischemic, requiring panretinal photocoagulation to prevent neovascular glaucoma 3.

Prognosis

Without treatment, 23% of CRVO patients achieve 20/200 or worse vision 3. With aggressive anti-VEGF therapy and removal of the prothrombotic trigger (olanzapine), visual prognosis improves significantly. The fellow eye requires close surveillance given the systemic hypercoagulable state and bilateral vascular engorgement.